Hansa Biopharma's Idefirix Used in First Commercial Kidney Transplant in Australia
Hansa Biopharma announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix (imlifidase). The treatment is approved for use.
Hansa Biopharma has announced that its drug Idefirix (imlifidase) has been used in the first commercial kidney transplant in Australia. The case involved a living donor kidney transplant.
The pharmaceutical company stated that the treatment has received approval and has now been utilized for the first time within Australia's commercial medical setting. Idefirix is indicated for patients with high antibody levels, facilitating kidney transplantation.
This marks a significant step in the drug's rollout in Australia. Hansa Biopharma anticipates that the drug will enable transplants for more patients in Australia by mitigating barriers related to antibody levels.
The company is listed on Nasdaq Stockholm under the ticker HNSA. The commercial introduction of Idefirix in Australia follows its prior approval in Europe.